// App-Quantinova.ai

TPS8572 : A Phase II Randomized, Placebo-Controlled Trial Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC ) Undergoing ChemoRadiation Therapy (CRT): A National Comprehensive Cancer Network-Sponsored Study.

Researchers

Presenter

  • Grace K. Dy

Principal Investigators

  • Eric S. Kim

  • Megan Ann Baumgart

  • Malcolm Mattes

  • Patrick C. Ma

  • Shirish M. Gadgeel

  • Julian R. Molina

  • Kristopher Attwood

  • Alex A. Adjei

Medical Centers

  • Roswell Park Cancer Institute, Buffalo, NY

  • University of Rochester, Rochester, NY

  • Yale University School of Medicine, New Haven, CT

  • West Virginia University, Morgantown, WV

  • Karmanos Cancer Institute, Detroit, MI

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Brain metastasis

  • Lung Cancer

  • Pulmonary alveolar proteinosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT02452463

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved